- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.01. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal ... | 47 | GlobeNewswire (Europe) | 27% preliminary response rate observed in heavily pre-treated microsatellite stable colorectal cancer (MSS CRC) patients without liver metastases Responses were accompanied by decreases in levels... ► Artikel lesen | |
| 21.01. | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 17.01. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 2 | GlobeNewswire (USA) | ||
| XILIO THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 10.01. | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | 129 | GlobeNewswire (Europe) | WALTHAM, Mass., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 19.12.24 | Gilead Sciences erwirbt Xilio Therapeutics-Aktien im Wert von 1,83 Millionen US-Dollar | 27 | Investing.com Deutsch | ||
| 19.12.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Initial Phase 2 Data for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab in Patients with Metastatic Microsatellite Stable Colorectal Cancer at ASCO ... | 1 | GlobeNewswire (USA) | ||
| 19.12.24 | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 16.12.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics Appoints Caroline Hensley as Chief Legal Officer | 1 | GlobeNewswire (USA) | ||
| 03.12.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 75 | GlobeNewswire (Europe) | WALTHAM, Mass., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 08.11.24 | Xilio Therapeutics reports Q3 results | 1 | Seeking Alpha | ||
| 07.11.24 | Xilio präsentiert neue Daten zur Krebsbehandlung auf der SITC-Konferenz | 2 | Investing.com Deutsch | ||
| 07.11.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Initial Clinical Trial Data from Phase 1C Dose Escalation for Vilastobart (XTX101), a Tumor-Activated Anti-CTLA-4, in Combination with Atezolizumab ... | 107 | GlobeNewswire (Europe) | Combination of vilastobart and atezolizumab demonstrated encouraging early evidence of anti-tumor activity, including unconfirmed partial responses observed in two patients with difficult-to-treat... ► Artikel lesen | |
| 07.11.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Pipeline and Business Updates and Third Quarter 2024 Financial Results | 90 | GlobeNewswire (Europe) | Will present initial Phase 1C dose escalation data for vilastobart (XTX101), a tumor-activated, Fc-enhanced anti-CTLA-4, in combination with atezolizumab, in a late-breaker poster presentation at... ► Artikel lesen | |
| 07.11.24 | Xilio Therapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 07.11.24 | Xilio Therapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 30.10.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present Initial Phase 1C Dose Escalation Data for XTX101 (Vilastobart) in Combination with Atezolizumab in a Late-Breaker Poster at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | 3 | GlobeNewswire (USA) | ||
| 04.10.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Upcoming Poster Presentation at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting | 1 | GlobeNewswire (USA) | ||
| 02.10.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | 114 | GlobeNewswire (Europe) | WALTHAM, Mass., Oct. 02, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies... ► Artikel lesen | |
| 13.09.24 | Xilio Therapeutics, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 28.08.24 | Xilio Therapeutics, Inc.: Xilio Therapeutics to Present at Morgan Stanley 22nd Annual Global Healthcare Conference | 1 | GlobeNewswire (USA) |
Seite:
1 2 Weiter >>
28 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PALATIN TECHNOLOGIES | 0,875 | +1,27 % | Palatin bereitet sich auf Adipositas-Behandlungsstudien im Jahr 2025 vor | ||
| BIOXXMED | 0,866 | 0,00 % | HV-Kalender: Aktionärs-Versammlungen u.a. bei bioXXmed, Deutsche Wohnen, fox e-mobility, Linus, ThyssenKrupp, Vonovia | Einmal jährlich müssen sich Aufsichtsrat und Vorstand einer Gesellschaft den Aktionären stellen: Die Hauptversammlung ist das höchste Organ einer Aktiengesellschaft und vergleichbarer Unternehmens-Formen.... ► Artikel lesen | |
| ORGANOVO | 0,333 | -0,60 % | Organovo, Inc.: Organovo Announces Appointment of Norman Staskey as Chief Financial Officer | SAN DIEGO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel disease... ► Artikel lesen | |
| OCUGEN | 0,716 | +1,35 % | Ocugen, Inc. Announces Investigational New Drug Application in Effect After Review by FDA to Initiate Phase 1 Clinical Trial Evaluating First-in-Class OCU500 Inhaled Vaccine Candidate for COVID-19 | OCU500 will be administered via inhalation and as a nasal sprayCOVID-19 remains a substantial public health threat in the U.S. and around the worldPhase 1 clinical trial is anticipated to start in... ► Artikel lesen | |
| SIRONA BIOCHEM | 0,039 | +10,00 % | Sirona Biochem präsentiert TFC-1326 in wegweisendem Bericht von Stonegate Healthcare | 15. Januar 2025 - Vancouver, British Columbia / IRW-Press / Sirona Biochem Corp. (TSX-V: SBM) (FWB:
ZSB) (OTC: SRBCF) freut sich bekannt zu geben, dass sein innovativer Anti-Aging-Wirkstoff TFC-1326... ► Artikel lesen | |
| BIO-GATE | 0,715 | -7,14 % | Bio-Gate: Prognose reduziert, Potenzial aber weiter hoch | Nach Darstellung von SMC-Research musste Bio-Gate wegen Auftragsverschiebungen die Jahresprognose für 2024 reduzieren. SMC-Analyst Holger Steffen sieht immer noch hohes Potenzial in dem Geschäft, aber... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,642 | -17,27 % | Best of BioTech 2025 - BioNTech, Bayer, Pfizer, BioNxt, Defence Therapeutics, Evotec und Vidac Pharma | Die biotechnologische Forschung wird 2025 von mehreren maßgeblichen Trends, Technologien und gesellschaftlichen Herausforderungen geprägt sein. Unter Einsatz von Wissen und Geld verspricht sich die... ► Artikel lesen | |
| VAXART | 0,710 | +2,60 % | Vaxart beruft neues Vorstandsmitglied mit Gesundheitsexpertise | ||
| BURCON NUTRASCIENCE | 0,055 | -5,48 % | Burcon NutraScience Corporation: Burcon Launches Groundbreaking Sunflower Protein Isolate | Vancouver, British Columbia--(Newsfile Corp. - January 8, 2025) - Burcon NutraScience Corporation (TSX: BU) (OTCQB: BRCNF) ("Burcon" or the "Company"), a global technology leader in the development... ► Artikel lesen | |
| AFFIMED | 0,924 | -2,33 % | Affimed N.V.: Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML) | AFM28, a bispecific, tetravalent innate cell engager (ICE®) targeting CD123 and CD16A, achieved a 40% composite complete remission rate (CRcR) at the highest dose level (300 mg) in heavily pretreated... ► Artikel lesen | |
| IMMUNIC | 0,936 | -0,79 % | EQS-News: Immunic AG: Immunic Highlights 2024 Accomplishments and Upcoming Milestones | Issuer: Immunic AG
/ Key word(s): Miscellaneous
Immunic Highlights 2024 Accomplishments and Upcoming Milestones
07.01.2025 / 12:30 CET/CEST
The issuer is solely responsible... ► Artikel lesen | |
| AIM IMMUNOTECH | 0,197 | +2,60 % | AIM ImmunoTech files to sell units, no amount given | ||
| T2 BIOSYSTEMS | 0,214 | +1,90 % | T2 Biosystems stock plunges to 52-week low of $0.22 | ||
| CEL-SCI | 0,400 | +8,75 % | CEL-SCI Reports Fiscal 2024 Results: Set to Commence Confirmatory Study That Could Bring New Standard of Care to Head & Neck Cancer | VIENNA, Va.--(BUSINESS WIRE)--CEL-SCI Corporation (NYSE American: CVM) reported financial results for the fiscal year ended September 30, 2024, as well as key clinical and corporate developments.
"We... ► Artikel lesen | |
| CELLECTAR BIOSCIENCES | 0,230 | -1,71 % | Cellectar Biosciences, Inc. - S-1, General form for registration of securities |
Das Unternehmen XILIO THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,708 Euro und damit -4,23 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu XILIO THERAPEUTICS INC finden Sie auf Wallstreet Online.
